09:53 AM EST - ProMIS Neurosciences, Inc. : Has issued a memorandum, compiled by its Executive Chairman of the Board, that provides context for the company's recent program progress as well as a white paper analysis of Biogen's October 22, decision to submit its amyloid-beta (AĆ)-targeting drug candidate, aducanumab for Alzheimer's disease to the U.S. Food and Drug administration in early 2020. The new resources detail how each development demonstrates strong momentum across the company's preclinical programs. ProMIS Neurosciences, Inc.
shares T.PMN are trading down $0.005 at $0.23.